The Modified Borg Dyspnea Scale does not predict hospitalization in pulmonary arterial hypertension

Debasree Banerjee, Jane Kamuren, Grayson L Baird, Amy Palmisciano, Ipsita Krishnan, Mary Whittenhall, James R Klinger, Corey E Ventetuolo, Debasree Banerjee, Jane Kamuren, Grayson L Baird, Amy Palmisciano, Ipsita Krishnan, Mary Whittenhall, James R Klinger, Corey E Ventetuolo

Abstract

Background Breathlessness is the most common symptom reported by patients with pulmonary arterial hypertension (PAH). The Modified Borg Dyspnea Scale (MBS) is routinely obtained during the six-minute walk test in the assessment of PAH patients, but it is not known whether the MBS predicts clinical outcomes such as hospitalizations in PAH. Methods We performed a retrospective study of World Health Organization (WHO) Group 1 PAH patients followed at our center. The dates of the first three MBS and hospitalizations that occurred within three months of a documented MBS were collected. Marginal Cox hazard regression modeling was used to assess for a relationship between MBS and all-cause as well as PAH-related hospitalization. Results A total of 50 patients were included; most (92%) were functional class III/IV, 44% and 65% were treatment-naïve prior to their first MBS and hospitalization, respectively. The first recorded MBS was inversely correlated with the first recorded six-minute walk distance (6MWD) (r = -0.41, P < 0.01) but did not track with WHO functional class (r = 0.07, P = 0.63). MBS did not predict all-cause (hazard ratio [HR], 0.91; 95% confidence interval [CI], 0.76-1.08; P = 0.28) or PAH-related hospitalization (HR, 1.04; 95% CI, 0.89-1.23; P = 0.61), though there was a strong relationship between 6MWD and PAH-related hospitalization ( P = 0.01). These findings persisted after multivariable adjustment. Conclusions Breathlessness as assessed by MBS does not predict all-cause or PAH-related hospitalization. Robust and validated patient-reported outcomes are needed in pulmonary vascular disease.

Keywords: Borg Scale; breathlessness; patient-reported outcomes; pulmonary hypertension; six-minute walk distance.

Figures

Fig. 1.
Fig. 1.
Marginal repeat hazards modeling for PAH-related hospitalization by MBS. X axis is the time to PAH-related hospitalization in days; Y axis is the likelihood of event. The legend corresponds to range of MBS representing each line.
Fig. 2.
Fig. 2.
Marginal repeat hazards modeling for PAH-related hospitalization by 6MWD. X axis is the time to PAH-related hospitalization in days; Y axis is the likelihood of event. The legend corresponds to range of 6MWD representing each line.

References

    1. Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104–109.
    1. Galie N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62(25 Suppl): D60–72.
    1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiography (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903–975.
    1. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142: 448–456.
    1. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012; 185: 435–452.
    1. McCabe C, Bennett M, Doughty N, et al. Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Chest 2013; 144: 522–530.
    1. Yorke J, Corris P, Gaine S, et al. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J 2014; 43: 1106–1113.
    1. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487–492.
    1. Tolle JJ, Waxman AB, Van Horn TL, et al. Exercise-induced pulmonary arterial hypertension. Circulation 2008; 118: 2183–2189.
    1. de Jesus Perez VA. Pumping it up! Angiogenesis and muscle deconditioning in pulmonary hypertension. Am J Respir Crit Care Med 2014; 190: 250–251.
    1. Borg E, Borg G, Larsson K, et al. An index for breathlessness and leg fatigue. Scand J Med Sci Sports 2010; 20: 644–650.
    1. Bausewein C, Farquhar M, Booth S, et al. Measurement of breathlessness in advanced disease: a systematic review. Respir Med 2007; 101: 399–410.
    1. Cenedese E, Speich R, Dorschner L, et al. Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J 2006; 28: 808–815.
    1. Channick RN, Delcroix M, Ghofrani HA, et al. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail 2015; 3: 1–8.
    1. Galie N, Barbera JA, Frost AE, et al. Initial Use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834–844.
    1. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522–2533.
    1. Holden DA, Rice TW, Stelmach K, et al. Exercise testing, 6-min walk, and stair climb in the evaluation of patients at high risk for pulmonary resection. Chest 1992; 102: 1774–1779.
    1. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377–381.
    1. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111–117.
    1. Mador MJ, Rodis A, Magalang UJ. Reproducibility of Borg scale measurements of dyspnea during exercise in patients with COPD. Chest 1995; 107: 1590–1597.
    1. Pesola GR, Ahsan H. Dyspnea as an independent predictor of mortality. Clin Respir J 2016; 10: 142–152.
    1. Maltoni M, Pirovano M, Scarpi E, et al. Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer 1995; 75: 2613–2622.
    1. Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434–1440.
    1. Yu TC, Zhou H, Suh K, et al. Assessing the importance of predictors in unplanned hospital readmissions for chronic obstructive pulmonary disease. Clinicoecon Outcomes Res 2015; 7: 37–51.
    1. Mahler DA, Faryniarz K, Tomlinson D, et al. Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease. Chest 1992; 102: 395–401.
    1. Schneider JE, Lewis LM, Ferguson I, et al. Repeated dyspnea score and percent FEV1 are modest predictors of hospitalization/relapse in patients with acute asthma exacerbation. Respir Med 2014; 108: 1284–1291.
    1. Nishiyama O, Taniguchi H, Kondoh Y, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J 2010; 36: 1067–1072.
    1. Khair RM, Nwaneri C, Damico RL, et al. The minimal important difference in Borg Dyspnea Score in pulmonary arterial hypertension. Ann Am Thorac Soc 2016; 13: 842–849.
    1. Chen H, Taichman DB, Doyle RL. Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension. Proc Am Thorac Soc 2008; 5: 623–630.
    1. Twiss J, McKenna S, Ganderton L, et al. Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension. BMC Pulm Med 2013; 13: 45.
    1. McCollister DH, Beutz M, McLaughlin V, et al. Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status. Psychosomatics 2010; 51: 339–339.e8.
    1. Chua R, Keogh AM, Byth K, et al. Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. Intern Med J 2006; 36: 705–710.
    1. Keogh AM, McNeil KD, Wlodarczyk J, et al. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant 2007; 26: 181–187.
    1. Bonner N, Abetz L, Meunier J, et al. Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients. Health Qual Life Outcomes 2013; 11: 161.
    1. Kirson NY, Birnbaum HG, Ivanova JI, et al. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population. Appl Health Econ Health Policy 2011; 9: 293–303.
    1. Burger CD, Long PK, Shah MR, et al. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry. Chest 2014; 146: 1263–1273.
    1. Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2011; 30: 632–643.
    1. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 1915–1922.
    1. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010–3019.
    1. McLaughlin VV, Badesch DB, Delcroix M, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54(1 Suppl): S97–107.
    1. Galie N, Simonneau G, Barst RJ, et al. Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Curr Opin Pulm Med 2010; 16(Suppl. 1): S11–19.
    1. Taichman DB, McGoon MD, Harhay MO, et al. Wide variation in clinicians’ assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. Mayo Clin Proc 2009; 84: 586–592.
    1. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780–788.
    1. Barst RJ, Chung L, Zamanian RT, et al. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest 2013; 144: 160–168.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa